{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:57:10Z","timestamp":1787950630266,"version":"build-2784847793"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The treatment paradigm for rectal cancer has been shifting toward de-escalated approaches to preserve patient quality of life. Historically, the standard treatment in the United States for locally advanced rectal cancer has standardly comprised preoperative chemoradiotherapy coupled with total mesorectal excision. Recent data challenge this \u201cone-size-fits-all\u201d strategy, supporting the possibility of omitting surgery for certain patients who achieve a clinical complete response to neoadjuvant therapy. Consequently, patients and their physicians must navigate diverse neoadjuvant options, often in the context of pursuing organ preservation. Total neoadjuvant therapy, involving the administration of all chemotherapy and radiation before total mesorectal excision, is associated with the highest rates of clinical complete response. However, questions persist regarding the optimal sequencing of radiation and chemotherapy and the choice between short-course and long-course radiation. Additionally, meticulous response assessment and surveillance are critical for selecting patients for nonoperative management without compromising the excellent cure rates associated with trimodality therapy. As nonoperative management becomes increasingly recognized as a standard-of-care treatment option for patients with rectal cancer, ongoing research in patient selection and monitoring as well as patient-reported outcomes is critical to guide personalized rectal cancer management within a patient-centered framework.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000727","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T08:06:36Z","timestamp":1721721996000},"page":"238-244","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Nonoperative Management for Rectal Cancer"],"prefix":"10.1097","volume":"30","author":[{"given":"Erqi L.","family":"Pollom","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul R.","family":"Sheth","sequence":"additional","affiliation":[{"name":"Body MRI Division, Department of Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron J.","family":"Dawes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Holden","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stanford University School of Medicine, Stanford, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20250928","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1056\/NEJMoa040694","article-title":"Preoperative versus postoperative chemoradiotherapy for rectal cancer","volume":"351","year":"2004","journal-title":"N Engl J Med"},{"key":"bib2-20250928","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1200\/JCO.2011.40.1836","article-title":"Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO\/ARO\/AIO-94 randomized phase III trial after a median follow-up of 11 years","volume":"30","year":"2012","journal-title":"J Clin Oncol"},{"key":"bib3-20250928","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa2303269","article-title":"Preoperative treatment of locally advanced rectal cancer","volume":"389","year":"2023","journal-title":"N Engl J Med"},{"key":"bib4-20250928","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1200\/JCO.23.00903","article-title":"Patient-reported outcomes during and after treatment for locally advanced rectal cancer in the PROSPECT trial (Alliance N1048)","volume":"41","year":"2023","journal-title":"J Clin Oncol"},{"key":"bib5-20250928","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/SLA.0000000000000594","article-title":"Comparative effectiveness of sphincter-sparing surgery versus abdominoperineal resection in rectal cancer: patient-reported outcomes in National Surgical Adjuvant Breast and Bowel Project Randomized Trial R-04","volume":"261","year":"2015","journal-title":"Ann Surg"},{"key":"bib6-20250928","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.radonc.2022.04.013","article-title":"Quality of life and late toxicity after short-course radiotherapy followed by chemotherapy or chemoradiotherapy for locally advanced rectal cancer\u2014the RAPIDO trial","volume":"171","year":"2022","journal-title":"Radiother Oncol"},{"key":"bib7-20250928","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S1470-2045(10)70172-8","article-title":"Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data","volume":"11","year":"2010","journal-title":"Lancet Oncol"},{"key":"bib8-20250928","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/01.sla.0000141194.27992.32","article-title":"Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy","volume":"240","year":"2004","journal-title":"Ann Surg"},{"key":"bib9-20250928","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S2468-1253(17)30074-2","article-title":"A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis","volume":"2","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"bib10-20250928","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/S0140-6736(18)31078-X","article-title":"Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study","volume":"391","year":"2018","journal-title":"Lancet"},{"key":"bib11-20250928","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.22.00032","article-title":"Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy","volume":"40","year":"2022","journal-title":"J Clin Oncol"},{"key":"bib12-20250928","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1470-2045(09)70381-X","article-title":"Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial","volume":"11","year":"2010","journal-title":"Lancet Oncol"},{"key":"bib13-20250928","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1634\/theoncologist.2014-0233","article-title":"Preoperative chemotherapy in patients with intermediate-risk rectal adenocarcinoma selected by high-resolution magnetic resonance imaging: the GEMCAD 0801 phase II multicenter trial","volume":"19","year":"2014","journal-title":"Oncologist"},{"key":"bib14-20250928","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1200\/JCO.23.01208","article-title":"Long-term results of organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy: the randomized phase II OPRA trial","volume":"42","year":"2024","journal-title":"J Clin Oncol"},{"key":"bib15-20250928","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1200\/JCO.2016.67.6049","article-title":"Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6)","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib16-20250928","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1470-2045(15)00004-2","article-title":"Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial","volume":"16","year":"2015","journal-title":"Lancet Oncol"},{"key":"bib17-20250928","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1200\/JCO.19.00308","article-title":"Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO\/ARO\/AIO-12","volume":"37","year":"2019","journal-title":"J Clin Oncol"},{"key":"bib18-20250928","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1200\/JCO.2012.42.9597","article-title":"Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group Trial 01.04","volume":"30","year":"2012","journal-title":"J Clin Oncol"},{"key":"bib19-20250928","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S1470-2045(11)70097-3","article-title":"Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial","volume":"12","year":"2011","journal-title":"Lancet Oncol"},{"key":"bib20-20250928","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1200\/JCO.2005.08.144","article-title":"Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate","volume":"23","year":"2005","journal-title":"J Clin Oncol"},{"key":"bib21-20250928","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1056\/NEJMoa010580","article-title":"Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer","volume":"345","year":"2001","journal-title":"N Engl J Med"},{"key":"bib22-20250928","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/annonc\/mdw062","article-title":"Long-course oxaliplatin-based preoperative chemoradiation versus 5 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study","volume":"27","year":"2016","journal-title":"Ann Oncol"},{"key":"bib23-20250928","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.radonc.2003.12.006","article-title":"Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy","volume":"72","year":"2004","journal-title":"Radiother Oncol"},{"key":"bib24-20250928","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S1470-2045(17)30086-4","article-title":"Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial","volume":"18","year":"2017","journal-title":"Lancet Oncol"},{"key":"bib25-20250928","article-title":"Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared to long-course chemoradiotherapy and surgery\u2014a five-year follow-up of the RAPIDO Trial","journal-title":"Ann Surg"},{"key":"bib26-20250928","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ijrobp.2021.10.004","article-title":"Clinical complete response in patients with rectal adenocarcinoma treated with short-course radiation therapy and nonoperative management","volume":"112","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4_suppl","key":"bib27-20250928","doi-asserted-by":"crossref","first-page":"TPS218","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS218","article-title":"Phase II trial of organ preservation program using short-course radiation and FOLFOXIRI for rectal cancer (SHORT-FOX)","volume":"40","year":"2022","journal-title":"J Clin Oncol"},{"key":"bib28-20250928","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1200\/JCO.2006.09.0928","article-title":"Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest","volume":"25","year":"2007","journal-title":"J Clin Oncol"},{"key":"bib29-20250928","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejca.2019.01.006","article-title":"Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial","volume":"110","year":"2019","journal-title":"Eur J Cancer"},{"key":"bib30-20250928","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial","volume":"22","year":"2021","journal-title":"Lancet Oncol"},{"key":"bib31-20250928","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(15)00120-5","article-title":"High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study","volume":"16","year":"2015","journal-title":"Lancet Oncol"},{"key":"bib32-20250928","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2468-1253(22)00392-2","article-title":"Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2\u2013cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial","volume":"8","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4_suppl","key":"bib33-20250928","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2023.41.4_suppl.7","article-title":"Long-term results from NRG-GI002: a phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)","volume":"41","year":"2023","journal-title":"J Clin Oncol"},{"key":"bib34-20250928","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1186\/s13063-017-2085-2","article-title":"A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial","volume":"18","year":"2017","journal-title":"Trials"},{"key":"bib35-20250928","doi-asserted-by":"crossref","first-page":"W486","DOI":"10.2214\/AJR.11.8210","article-title":"MRI after treatment of locally advanced rectal cancer: how to report tumor response\u2014the MERCURY experience","volume":"199","year":"2012","journal-title":"Am J Roentgenol"},{"key":"bib36-20250928","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.2011.34.9068","article-title":"Magnetic resonance imaging\u2013detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience","volume":"29","year":"2011","journal-title":"J Clin Oncol"},{"key":"bib37-20250928","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1245\/s10434-012-2309-3","article-title":"Comparison of magnetic resonance imaging and histopathological response to chemoradiotherapy in locally advanced rectal cancer","volume":"19","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"bib38-20250928","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.crad.2016.05.005","article-title":"Interobserver agreement of radiologists assessing the response of rectal cancers to preoperative chemoradiation using the MRI tumour regression grading (mrTRG)","volume":"71","year":"2016","journal-title":"Clin Radiol"},{"key":"bib39-20250928","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1148\/rg.2019180114","article-title":"MRI of rectal cancer: tumor staging, imaging techniques, and management","volume":"39","year":"2019","journal-title":"Radiographics"},{"key":"bib40-20250928","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s00330-017-5026-2","article-title":"Magnetic resonance imaging for clinical management of rectal cancer: updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting","volume":"28","year":"2018","journal-title":"Eur Radiol"},{"key":"bib41-20250928","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1186\/s12885-015-1632-z","article-title":"Organ preservation in rectal adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management","volume":"15","year":"2015","journal-title":"BMC Cancer"},{"key":"bib42-20250928","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2214\/AJR.16.17242","article-title":"Modified 3-point MRI-based tumor regression grade incorporating DWI for locally advanced rectal cancer","volume":"209","year":"2017","journal-title":"Am J Roentgenol"},{"key":"bib43-20250928","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1007\/s00261-023-03961-7","article-title":"Predicting response to chemoradiotherapy in rectal cancer via visual morphologic assessment and staging on baseline MRI: a multicenter and multireader study","volume":"48","year":"2023","journal-title":"Abdom Radiol (NY)"},{"key":"bib44-20250928","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/DCR.0000000000000915","article-title":"A pattern-based approach combining tumor morphology on MRI with distinct signal patterns on diffusion-weighted imaging to assess response of rectal tumors after chemoradiotherapy","volume":"61","year":"2018","journal-title":"Dis Colon Rectum"},{"key":"bib45-20250928","doi-asserted-by":"crossref","first-page":"3873","DOI":"10.1245\/s10434-015-4687-9","article-title":"Assessment of clinical complete response after chemoradiation for rectal cancer with digital rectal examination, endoscopy, and MRI: selection for organ-saving treatment","volume":"22","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"bib46-20250928","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/DCR.0000000000000558","article-title":"Pathologic complete response in rectal cancer: can we detect it? Lessons learned from a proposed randomized trial of watch-and-wait treatment of rectal cancer","volume":"59","year":"2016","journal-title":"Dis Colon Rectum"},{"key":"bib47-20250928","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.ejso.2018.11.019","article-title":"Response assessment after (chemo)radiotherapy for rectal cancer: why are we missing complete responses with MRI and endoscopy?","volume":"45","year":"2019","journal-title":"Eur J Surg Oncol"},{"issue":"15_suppl","key":"bib48-20250928","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1200\/JCO.2021.39.15_suppl.3509","article-title":"Survival and organ preservation according to clinical response after total neoadjuvant therapy in locally advanced rectal cancer patients: a secondary analysis from the Organ Preservation in Rectal Adenocarcinoma (OPRA) trial","volume":"39","year":"2021","journal-title":"J Clin Oncol"},{"key":"bib49-20250928","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1097\/DCR.0000000000000667","article-title":"Magnetic resonance tumor regression grade and residual mucosal abnormality as predictors for pathological complete response in rectal cancer postneoadjuvant chemoradiotherapy","volume":"59","year":"2016","journal-title":"Dis Colon Rectum"},{"key":"bib50-20250928","doi-asserted-by":"crossref","first-page":"e185896","DOI":"10.1001\/jamaoncol.2018.5896","article-title":"Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant therapy","volume":"5","year":"2019","journal-title":"JAMA Oncol"},{"key":"bib51-20250928","doi-asserted-by":"crossref","first-page":"E171","DOI":"10.1016\/j.ijrobp.2019.06.2155","article-title":"Cost effectiveness of watch-and-wait or total mesorectal excision after complete clinical response to chemoradiotherapy for rectal cancer","volume":"105","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib52-20250928","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.prro.2020.08.004","article-title":"Radiation therapy for rectal cancer: executive summary of an ASTRO clinical practice guideline","volume":"11","year":"2021","journal-title":"Pract Radiat Oncol"},{"key":"bib53-20250928","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(20)30557-X","article-title":"Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study","volume":"22","year":"2021","journal-title":"Lancet Oncol"},{"key":"bib54-20250928","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.3390\/tomography8060227","article-title":"FDG-PET\/MRI for nonoperative management of rectal cancer: a prospective pilot study","volume":"8","year":"2022","journal-title":"Tomography"},{"key":"bib55-20250928","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12876-019-1036-7","article-title":"Diagnostic performance of gadoxetic acid\u2013enhanced liver MRI versus multidetector CT in the assessment of colorectal liver metastases compared to hepatic resection","volume":"19","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"bib56-20250928","first-page":"224ra24","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","year":"2014","journal-title":"Sci Transl Med"},{"key":"bib57-20250928","first-page":"346ra92","article-title":"Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer","volume":"8","year":"2016","journal-title":"Sci Transl Med"},{"key":"bib58-20250928","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ejso.2011.01.025","article-title":"The clinical significance of circulating tumor cells in non-metastatic colorectal cancer\u2014a review","volume":"37","year":"2011","journal-title":"Eur J Surg Oncol"},{"key":"bib59-20250928","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/DCR.0000000000001166","article-title":"Patient and physician preferences for nonoperative management for low rectal cancer: is it a reasonable treatment option?","volume":"61","year":"2018","journal-title":"Dis Colon Rectum"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000727","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T07:00:39Z","timestamp":1759042839000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000727","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]}}}